The results imply that inhibiting Cdc42 in hyperglycemia may be a potential therapy for promoting tissue regeneration in diabetes, and so should help for various diabetic complications, e.g. the diabetic foot or stroke. This evidence concerns the gene CDC42 and Stroke.